Comparative Effects of Autogenic Inhibition vs Reciprocal Inhibition in Patients With Lower Cross Syndrome

September 18, 2026 updated by: Foundation University Islamabad

This randomized controlled trial aims to compare the effectiveness of Autogenic Inhibition Muscle Energy Technique (MET) and Reciprocal Inhibition MET in individuals with Lower Crossed Syndrome. Participants will be randomly assigned to two intervention groups. One group will receive Autogenic Inhibition MET, while the other will receive Reciprocal Inhibition MET for the iliopsoas, rectus femoris, and erector spinae muscles. Both groups will also perform the same standardized strengthening exercises targeting the transversus abdominis, gluteus maximus, and gluteus medius muscles to improve muscle balance and functional outcomes.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Participants who meet the eligibility criteria and provide informed consent will be randomly allocated into two experimental groups using a randomization method. The intervention will be carried out over a period of six weeks, with three treatment sessions per week, making a total of 18 sessions for each participant. Before the commencement of each treatment session, all participants will receive a 10-minute hot pack application over the lumbar region to promote muscle relaxation, reduce soft tissue stiffness, and prepare the muscles for manual therapy. Following the hot pack, participants will receive the assigned Muscle Energy Technique (MET) according to their respective group.

Participants in Experimental Group 1 will receive Autogenic Inhibition Muscle Energy Technique (Modified Post-Facilitation Stretch Protocol) targeting the iliopsoas, rectus femoris, and erector spinae muscles. The therapist will position the involved muscle at its initial barrier, after which the participant will perform an isometric contraction of approximately 20-30% of maximal effort for 7-10 seconds against the therapist's resistance. After relaxation, the muscle will be gently stretched to the new barrier and the stretch will be maintained for 30 seconds. This procedure will be repeated 3-5 times for each muscle during every treatment session.

Participants in Experimental Group 2 will receive Reciprocal Inhibition Muscle Energy Technique for the same muscle groups. The therapist will position the muscle at the initial barrier, and the participant will perform an isometric contraction of the antagonist muscle using approximately 20-30% of maximal effort for 7-10 seconds. Following relaxation, the therapist will move the muscle to the new barrier and maintain the stretch for 30 seconds. The technique will also be repeated 3-5 times for each targeted muscle during every treatment session.

Both groups will follow an identical strengthening exercise program to address the weak muscles commonly associated with Lower Crossed Syndrome. The strengthening program will target the transversus abdominis, gluteus maximus, and gluteus medius muscles using progressive therapeutic exercises prescribed according to the participant's tolerance. During the first two weeks, the intervention will primarily emphasize improving flexibility and reducing muscle tightness through the assigned MET. From Week 3 to Week 6, participants will continue receiving their allocated MET while simultaneously performing the strengthening exercises to restore muscle balance, improve lumbopelvic stability, and enhance functional performance. Exercise intensity and repetitions will be progressed gradually throughout the intervention while maintaining proper technique and patient comfort.

The treatment duration, session frequency, hot pack application, strengthening protocol, therapist supervision, and progression of exercises will remain identical for both groups. The only difference between the two groups will be the type of Muscle Energy Technique employed-Autogenic Inhibition MET in Experimental Group 1 and Reciprocal Inhibition MET in Experimental Group 2. Outcome measures will be recorded before and after completion of the intervention period to evaluate the comparative effectiveness of both treatment approaches in improving pain, muscle flexibility, lumbar range of motion, posture, and functional disability among individuals with Lower Crossed Syndrome.

Study Type

Interventional

Enrollment (Estimated)

46

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Punjab Province
      • Islamabad, Punjab Province, Pakistan, 44000
        • Recruiting
        • Foundation University College of Physical Therapy
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years to 35 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria

  • Age 19-35 years.
  • Both genders will include in this study.
  • According to Janda's Approach, Clinical diagnosis of LCS based on ≥3 positive clinical tests.
  • Patient with positive modified Thomas test, Patients with a positive testing of prone hip extension test, Patients with a positive test of trunk flexion test, Patients with tight erector spinae muscles.
  • Participants with no lumbar pain to moderate lumbar pain (NPRS0-6) will be included.
  • Painless movement and activity.
  • Pain only produced by sustained loading in relevant position, which is then relieved after maintaining a corrected posture for 5 minutes, indicating posture-related pain.

Exclusion Criteria

  • Leg symptoms when walking, eased in flexion (Signs of stenosis)
  • Pain due to repetitive movement
  • Lumbar Radiculopathy
  • Neurological Symptoms (Paresthesia/numbness)
  • Structural deformity (Kyphosis, lordosis, scoliosis, spondylosis, spondylolysis, spondylolisthesis)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Autogenic Inhibtion (Group A)

Group A will receive Autogenic inhibition using PFS, preceded by 10 minutes heating pad application. 30% Isometric contraction(7-10 sec), followed by relaxation & 30 sec stretch, will be repeated 3-5 time. From Weeks 3-6, strenghtening exercises for hip extensors & Transverse Abdominis will be performed.

Experimental Group 1 will receive MET based on autogenic inhibition using Modified Post-Facilitation Stretch (PFS) for the iliopsoas, rectus femoris, and erector spinae. For the iliopsoas, subjects will assume modified Thomas position and perform a 30% isometric contraction for 7-10 seconds, followed by relaxation and hip extension stretching for 30 seconds. For rectus femoris, the procedure will be performed in modified Thomas position with knee flexion, followed by hip extension and knee flexion stretching for 30 seconds. For erector spinae, subjects will sit with legs hanging and arms crossed, perform a 30% isometric contraction for 7-10 seconds, followed by trunk flexion for 30 seconds. Each technique will include 30-second rest and 3-5 repetitions. From the 3rd to 6th week, strengthening will include TA activation, gluteus maximus bridging, and gluteus medius abduction.

Experimental: Reciprocal Inhibition (Group B)

Group B will receive Reciprocal Inhibition using using MET,preceding by a 10 minute heating pad application. A 30% isometric contraction(7-10 sec) of antagonist muscle, followed by relaxation & 30-60sec passive stretch, will be repeated 3-5 times. From 3-6 weeks strenghening exercises for hip extensor & transverse abdominis will be performed.

Experimental Group 2 will receive MET based on reciprocal inhibition for the iliopsoas, rectus femoris, and erector spinae. For the iliopsoas, subjects will assume modified Thomas position and perform a 30% isometric contraction of the gluteus maximus for 7-10 seconds, followed by relaxation and passive hip extension stretching for 30-60 seconds. For rectus femoris, subjects will assume modified Thomas position followed by a 30% isometric hamstring contraction for 7-10 seconds and passive stretching into hip extension with knee flexion for 30-60 seconds. For Erector Spinae, subjects will sit with legs hanging and perform a 30% isometric transverse abdominis contraction for 7-10 seconds, followed by trunk flexion for 30-60 seconds. From the 3rd to 6th week, strengthening will include TA activation, gluteus maximus bridging, and gluteus medius abduction.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Lumbar Extensor Muscle Length
Time Frame: Baseline & after 6 weeks of intervention.

The Modified Schober's Test will be used to assess lumbar extensor muscle length and lumbar spine mobility. The increase in distance between standardized spinal landmarks during maximal forward flexion will be measured and recorded in centimeters (cm). A greater increase in distance indicates greater lumbar extensor flexibility or length.

Baseline & after 6 weeks of intervention.
Functional Movement dysfunction
Time Frame: Baseline and after 6 Weeks of intervention.

Functional Movement Screen will be used to assess functional movement dysfunction. It consists of seven tests, scored on a 0-3 scale, with a total score ranging from 0 to 21. Lower scores indicate greater movement dysfunction.

Baseline and after 6 Weeks of intervention.
Back Pain
Time Frame: Baseline and after 6 Weeks of intervention.

Pain intensity will be assessed using the Numerical Pain Rating Scale, ranging from 0 (no pain) to 10 (worst possible pain). Participants reporting pain intensity scores of 0-6 on the NPRS will be eligible for inclusion in the study.

Baseline and after 6 Weeks of intervention.
Functional Disability
Time Frame: Baseline and after 6 Weeks of intervention

Functional disability will be assessed using the Oswestry Disability Index (ODI), a 10-item questionnaire, with each item consisting of six response options.

Baseline and after 6 Weeks of intervention
Lumbar Range Of Motion
Time Frame: Baseline and after 6 Weeks of invention

Lumbar spine range of motion (ROM) will be assessed using inclinometer, including lumbar flexion, extension, and lateral flexion. Lumbar ROM will be determined by measuring the difference between the readings obtained at the T12 and S2 spinal landmarks.

Baseline and after 6 Weeks of invention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 12, 2026

Primary Completion (Estimated)

December 18, 2026

Study Completion (Estimated)

January 18, 2027

Study Registration Dates

First Submitted

September 18, 2026

First Submitted That Met QC Criteria

September 18, 2026

First Posted (Actual)

September 24, 2026

Study Record Updates

Last Update Posted (Actual)

September 24, 2026

Last Update Submitted That Met QC Criteria

September 18, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • FUI/FUCP/CTR/MSMSK/MomnaKhadim

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.